Metabolic response rates of epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data
Authors
Falchi, L.Clausen, M.
Offner, F.
De Vos, S.
Brody, J.
Linton, Kim M
Snauwaert, S.
Cordoba, R.
Wu, J.
Bykhovski, I.
Wang, L.
Rana, A.
Belada, D.
Affiliation
Lymphoma Service, Memorial Sloan Kettering Cancer Center, New York, NYIssue Date
2023
Metadata
Show full item recordCitation
Falchi L, Clausen M, Offner F, De Vos S, Brody J, Linton KM, et al. Metabolic response rates of epcoritamab plus R-CHOP in patients with previously untreated (1L) high-risk diffuse large B-cell lymphoma, including double-hit/triple-hit lymphoma: Updated EPCORE NHL-2 data. Journal of Clinical Oncology. 2023 Jun;41(16). PubMed PMID: WOS:001053772003462.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2023.41.16_suppl.7519Additional Links
https://dx.doi.org/10.1200/JCO.2023.41.16_suppl.7519Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2023.41.16_suppl.7519